Limited adoption of model-informed drug development
If regulators or academic institutions resist these methods, demand for the company's tools and services can weaken.
- Scope
- Biopharma software and consulting demand
- Materiality
- high
Simulations Plus, Inc.
Simulations Plus, Inc. develops software and consulting services used in biopharma research, drug development, clinical trials, and commercialization. The company is based in the United States and operates through wholly owned subsidiaries, serving customers globally across the drug development lifecycle.
−79,0 %
58,4 %
−81,7 %
+13,1 %
7.67
7.67
| % | |
|---|---|
| Software | 58% Scientific software platforms used for biosimulation, modeling, and drug development workflows. |
| Services | 42% Consulting, customization, and expert support for drug discovery and development programs. |
Customers are primarily biopharma organizations that use modeling and simulation to improve drug discovery,...
- Pharmaceutical companiesprimary
Buy software and consulting to support discovery, clinical development, and commercialization decisions.
- Biotechnology companiesprimary
Use the platform and expert services to supplement limited internal modeling resources.
- Research institutions and government organizationssecondary
Use the software for scientific research, training, and applied drug-development studies.
- Non-pharma industriesemerging
Agrotechnology and cosmetics customers use selected tools for modeling and scientific analysis.
The company markets its software and services globally, with sales and marketing activity spanning scientific meetings,...
- •United States is the corporate base and a major operating market
- •Global commercial reach through scientific meetings and direct sales
- •Independent distributors in Japan, China, India, South Korea, and Brazil
- •International pharma hubs matter because customers are research-intensive
- •Regulatory and scientific adoption varies by region and affects demand
The company is focused on expanding use of its software and services across the full drug development lifecycle, from...
01
Expand existing client relationshipsshort-term
Deeper adoption increases software and services revenue per account and strengthens retention.
02
Account-based solution sellingshort-term
Selling integrated solutions improves relevance to client pain points and supports scalable growth.
03
Strategic acquisitions and partnershipsmedium-term
External growth can add capabilities, customers, and market access in adjacent areas.
Demand depends on continued acceptance of model-informed drug development, regulatory support, and customers'...
Competitive pressure from larger and adjacent providers
Competitors include established software firms, CROs, consulting groups, and in-house pharma teams with greater resources.
- Scope
- Software licenses and consulting engagements
- Materiality
- high
Dependence on client budgets and outsourcing decisions
Customers may reduce spending or bring work in-house, lowering software and services demand.
- Scope
- Pharma and biotech customer base
- Materiality
- high
AI and machine learning deployment risk
Flawed models, poor datasets, or harmful outputs could damage reputation and create legal or regulatory exposure.
- Scope
- AI-augmented software and analytics
- Materiality
- medium
Revenue recognition
Affects quarterly revenue mix and comparability
Capitalized software development costs
Impacts operating expense and intangible assets
Goodwill and intangible assets
Can create non-cash impairment charges
Stock-based compensation
Affects reported profitability and dilution
: 29.4.2026